Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy.

Hirukawa A, Singh S, Wang J, Rennhack JP, Swiatnicki M, Sanguin-Gendreau V, Zuo D, Daldoul K, Lavoie C, Park M, Andrechek ER, Westbrook TF, Harris LN, Varadan V, Smith HW, Muller WJ.

Cell Rep. 2019 Oct 8;29(2):249-257.e8. doi: 10.1016/j.celrep.2019.08.105.

2.

Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q.

Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.

Ann Oncol. 2019 Aug 27. pii: mdz291. doi: 10.1093/annonc/mdz291. [Epub ahead of print]

PMID:
31504139
3.

An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.

Smith HW, Hirukawa A, Sanguin-Gendreau V, Nandi I, Dufour CR, Zuo D, Tandoc K, Leibovitch M, Singh S, Rennhack JP, Swiatnicki M, Lavoie C, Papavasiliou V, Temps C, Carragher NO, Unciti-Broceta A, Savage P, Basik M, van Hoef V, Larsson O, Cooper CL, Vargas Calderon AC, Beith J, Millar E, Selinger C, Giguère V, Park M, Harris LN, Varadan V, Andrechek ER, O'Toole SA, Topisirovic I, Muller WJ.

Nat Commun. 2019 Jul 1;10(1):2901. doi: 10.1038/s41467-019-10681-4.

4.

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer.

Braman N, Prasanna P, Whitney J, Singh S, Beig N, Etesami M, Bates DDB, Gallagher K, Bloch BN, Vulchi M, Turk P, Bera K, Abraham J, Sikov WM, Somlo G, Harris LN, Gilmore H, Plecha D, Varadan V, Madabhushi A.

JAMA Netw Open. 2019 Apr 5;2(4):e192561. doi: 10.1001/jamanetworkopen.2019.2561.

5.

Premature alarm on the impacts of climate change on Arctic Char in Lake Hazen.

Moore JS, Chapman JM, Mazerolle MJ, Harris LN, Taylor EB.

Nat Commun. 2018 Sep 28;9(1):3985. doi: 10.1038/s41467-018-06479-5. No abstract available.

6.

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.

Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, Hyslop TM, Pitcher BN, Soloway MG, Spears PA, Henry LN, Tolaney S, Dang CT, Krop IE, Harris LN, Berry DA, Mardis ER, Winer EP, Hudis CA, Carey LA, Perou CM.

Clin Cancer Res. 2018 Nov 1;24(21):5292-5304. doi: 10.1158/1078-0432.CCR-17-3431. Epub 2018 Jul 23.

7.

From top to bottom: Do Lake Trout diversify along a depth gradient in Great Bear Lake, NT, Canada?

Chavarie L, Howland KL, Harris LN, Hansen MJ, Harford WJ, Gallagher CP, Baillie SM, Malley B, Tonn WM, Muir AM, Krueger CC.

PLoS One. 2018 Mar 22;13(3):e0193925. doi: 10.1371/journal.pone.0193925. eCollection 2018.

8.

Individual Differences in Phonological Feedback Effects: Evidence for the Orthographic Recoding Hypothesis of Orthographic Learning.

Harris LN, Perfetti C.

Sci Stud Read. 2017;21(1):31-45. doi: 10.1080/10888438.2016.1258702. Epub 2016 Dec 23.

9.

Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.

Nunes AT, Collyar DE, Harris LN.

JNCI Cancer Spectr. 2017 Dec 11;1(1):pkx008. doi: 10.1093/jncics/pkx008. eCollection 2017 Sep. Review.

10.

Genomics and telemetry suggest a role for migration harshness in determining overwintering habitat choice, but not gene flow, in anadromous Arctic Char.

Moore JS, Harris LN, Le Luyer J, Sutherland BJG, Rougemont Q, Tallman RF, Fisk AT, Bernatchez L.

Mol Ecol. 2017 Dec;26(24):6784-6800. doi: 10.1111/mec.14393. Epub 2017 Nov 30.

PMID:
29087005
11.

The Challenge for Development of Valuable Immuno-oncology Biomarkers.

Mehnert JM, Monjazeb AM, Beerthuijzen JMT, Collyar D, Rubinstein L, Harris LN.

Clin Cancer Res. 2017 Sep 1;23(17):4970-4979. doi: 10.1158/1078-0432.CCR-16-3063.

12.

Sex matters in massive parallel sequencing: Evidence for biases in genetic parameter estimation and investigation of sex determination systems.

Benestan L, Moore JS, Sutherland BJG, Le Luyer J, Maaroufi H, Rougeux C, Normandeau E, Rycroft N, Atema J, Harris LN, Tallman RF, Greenwood SJ, Clark FK, Bernatchez L.

Mol Ecol. 2017 Dec;26(24):6767-6783. doi: 10.1111/mec.14217. Epub 2017 Jul 24.

PMID:
28658525
13.

Chronic and episodic stress predict physical symptom bother following breast cancer diagnosis.

Harris LN, Bauer MR, Wiley JF, Hammen C, Krull JL, Crespi CM, Weihs KL, Stanton AL.

J Behav Med. 2017 Dec;40(6):875-885. doi: 10.1007/s10865-017-9855-x. Epub 2017 May 20.

14.

"A rising tide lifts all boats": establishing a multidisciplinary genomic tumor board for breast cancer patients with advanced disease.

McGowan ML, Ponsaran RS, Silverman P, Harris LN, Marshall PA.

BMC Med Genomics. 2016 Nov 21;9(1):71.

15.

Reply to D.C. Sgroi et al, T. Sanft et al, M.S. Copur et al, and M.P. Goetz et al.

Harris LN, Ismaila N, McShane LM, Andre F.

J Clin Oncol. 2016 Nov 10;34(32):3946-3948. doi: 10.1200/JCO.2016.68.7020. No abstract available.

PMID:
27551123
16.

Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.

Merry CR, McMahon S, Forrest ME, Bartels CF, Saiakhova A, Bartel CA, Scacheri PC, Thompson CL, Jackson MW, Harris LN, Khalil AM.

Oncotarget. 2016 Aug 16;7(33):53230-53244. doi: 10.18632/oncotarget.10637.

17.

"An addendum to breast cancer": the triple negative experience.

Turkman YE, Kennedy HP, Harris LN, Knobf MT.

Support Care Cancer. 2016 Sep;24(9):3715-21. doi: 10.1007/s00520-016-3184-4. Epub 2016 Apr 1.

PMID:
27037812
18.

Biomarkers for Predicting Response to Anti-HER2 Agents.

Varadan V, Sandoval M, Harris LN.

Adv Exp Med Biol. 2016;882:155-67. doi: 10.1007/978-3-319-22909-6_6. Review.

PMID:
26987534
19.

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, Winer EP, Krop IE, Zhao JJ.

Cancer Cell. 2016 Mar 14;29(3):255-269. doi: 10.1016/j.ccell.2016.02.006.

20.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary.

Harris LN, Ismaila N, McShane LM, Hayes DF.

J Oncol Pract. 2016 Apr;12(4):384-9. doi: 10.1200/JOP.2016.010868. Epub 2016 Mar 8. No abstract available.

PMID:
26957642
21.

Lexical Stress and Linguistic Predictability Influence Proofreading Behavior.

Harris LN, Perfetti CA.

Front Psychol. 2016 Feb 9;7:96. doi: 10.3389/fpsyg.2016.00096. eCollection 2016.

22.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF; American Society of Clinical Oncology.

J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200/JCO.2015.65.2289. Epub 2016 Feb 8. Review.

23.

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer.

Varadan V, Gilmore H, Miskimen KL, Tuck D, Parsai S, Awadallah A, Krop IE, Winer EP, Bossuyt V, Somlo G, Abu-Khalaf MM, Fenton MA, Sikov W, Harris LN.

Clin Cancer Res. 2016 Jul 1;22(13):3249-59. doi: 10.1158/1078-0432.CCR-15-2021. Epub 2016 Feb 3.

24.

Dispositional and Situational Avoidance and Approach as Predictors of Physical Symptom Bother Following Breast Cancer Diagnosis.

Bauer MR, Harris LN, Wiley JF, Crespi CM, Krull JL, Weihs KL, Stanton AL.

Ann Behav Med. 2016 Jun;50(3):370-84. doi: 10.1007/s12160-015-9763-7.

25.

Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma.

Bomeisl PE, Thompson CL, Harris LN, Gilmore HL.

Arch Pathol Lab Med. 2015 Dec;139(12):1546-9. doi: 10.5858/arpa.2014-0557-OA.

PMID:
26619027
26.

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA.

J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2.

27.

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Van Poznak C, Harris LN, Somerfield MR.

J Oncol Pract. 2015 Nov;11(6):514-516. doi: 10.1200/JOP.2015.005215. No abstract available.

PMID:
29424583
28.

Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers.

Varadan V, Kamalakaran S, Gilmore H, Banerjee N, Janevski A, Miskimen KL, Williams N, Basavanhalli A, Madabhushi A, Lezon-Geyda K, Bossuyt V, Lannin DR, Abu-Khalaf M, Sikov W, Dimitrova N, Harris LN.

Int J Cancer. 2016 Feb 1;138(3):747-57. doi: 10.1002/ijc.29808. Epub 2015 Aug 31.

29.

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes DF, Harris LN.

J Clin Oncol. 2015 Aug 20;33(24):2695-704. doi: 10.1200/JCO.2015.61.1459. Epub 2015 Jul 20.

30.

Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancer.

Merry CR, McMahon S, Thompson CL, Miskimen KL, Harris LN, Khalil AM.

Breast Cancer Res Treat. 2015 Apr;150(2):321-34. doi: 10.1007/s10549-015-3327-1. Epub 2015 Mar 8.

PMID:
25749757
31.

Biologic, demographic, and social factors affecting triple negative breast cancer outcomes.

Turkman YE, Sakibia Opong A, Harris LN, Knobf MT.

Clin J Oncol Nurs. 2015 Feb;19(1):62-7. doi: 10.1188/15.CJON.62-67. Review.

PMID:
25689650
32.

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.

Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN.

Cancer. 2015 Jun 1;121(11):1817-26. doi: 10.1002/cncr.29254. Epub 2015 Feb 3.

33.

Project connect online: user and visitor experiences of an Internet-based intervention for women with breast cancer.

Harris LN, Cleary EH, Stanton AL.

Psychooncology. 2015 Sep;24(9):1145-51. doi: 10.1002/pon.3734. Epub 2014 Dec 17.

34.

Evolution and origin of sympatric shallow-water morphotypes of Lake Trout, Salvelinus namaycush, in Canada's Great Bear Lake.

Harris LN, Chavarie L, Bajno R, Howland KL, Wiley SH, Tonn WM, Taylor EB.

Heredity (Edinb). 2015 Jan;114(1):94-106. doi: 10.1038/hdy.2014.74. Epub 2014 Sep 10.

36.

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.

Cheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL.

BMC Cancer. 2014 May 8;14:326. doi: 10.1186/1471-2407-14-326.

37.

Error-related negativities during spelling judgments expose orthographic knowledge.

Harris LN, Perfetti CA, Rickles B.

Neuropsychologia. 2014 Feb;54:112-28. doi: 10.1016/j.neuropsychologia.2013.12.007. Epub 2013 Dec 31.

38.

Genetic analysis of sympatric migratory ecotypes of Arctic charr Salvelinus alpinus: alternative mating tactics or reproductively isolated strategies?

Moore JS, Loewen TN, Harris LN, Tallman RF.

J Fish Biol. 2014 Jan;84(1):145-62. doi: 10.1111/jfb.12262.

PMID:
24383802
39.

The renaissance of endocrine therapy in breast cancer.

Williams N, Harris LN.

Curr Opin Obstet Gynecol. 2014 Feb;26(1):41-7. doi: 10.1097/GCO.0000000000000039. Review.

PMID:
24346127
40.

Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy.

Lindner R, Sullivan C, Offor O, Lezon-Geyda K, Halligan K, Fischbach N, Shah M, Bossuyt V, Schulz V, Tuck DP, Harris LN.

PLoS One. 2013 Nov 18;8(11):e71915. doi: 10.1371/journal.pone.0071915. eCollection 2013.

41.

Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, Harris LN, Ingle JN, Lingle WL, Perez EA.

Clin Cancer Res. 2013 Oct 15;19(20):5798-807. doi: 10.1158/1078-0432.CCR-13-0558. Epub 2013 Aug 21.

42.

Early stage visual-orthographic processes predict long-term retention of word form and meaning: a visual encoding training study.

Cao F, Rickles B, Vu M, Zhu Z, Chan DH, Harris LN, Stafura J, Xu Y, Perfetti CA.

J Neurolinguistics. 2013 Jul 1;26(4):440-461.

43.

Translating next generation sequencing to practice: opportunities and necessary steps.

Kamalakaran S, Varadan V, Janevski A, Banerjee N, Tuck D, McCombie WR, Dimitrova N, Harris LN.

Mol Oncol. 2013 Aug;7(4):743-55. doi: 10.1016/j.molonc.2013.04.008. Epub 2013 May 15. Review.

44.

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.

Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Reinholz MM.

J Clin Oncol. 2013 Jun 10;31(17):2115-22. doi: 10.1200/JCO.2012.42.2642. Epub 2013 May 6.

45.

HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade.

Kim YJ, Greer CB, Cecchini KR, Harris LN, Tuck DP, Kim TH.

Oncogene. 2013 Jun 6;32(23):2828-35. doi: 10.1038/onc.2013.32. Epub 2013 Feb 25.

46.

Microsatellite and mtDNA analysis of lake trout, Salvelinus namaycush, from Great Bear Lake, Northwest Territories: impacts of historical and contemporary evolutionary forces on Arctic ecosystems.

Harris LN, Howland KL, Kowalchuk MW, Bajno R, Lindsay MM, Taylor EB.

Ecol Evol. 2012 Jan;3(1):145-61. doi: 10.1002/ece3.439. Epub 2012 Dec 14.

47.

Gene flow and effective population size in two life-history types of broad whitefish Coregonus nasus from the Canadian Arctic.

Harris LN, Taylor EB, Tallman RF, Reist JD.

J Fish Biol. 2012 Jul;81(1):288-307. doi: 10.1111/j.1095-8649.2012.03339.x. Epub 2012 Jun 6.

PMID:
22747819
48.

DTCs/CTCs in breast cancer: five decades later.

Alsamarai S, Abu-Khalaf MM, Harris LN.

Recent Results Cancer Res. 2012;195:217-25. doi: 10.1007/978-3-642-28160-0_20. Review.

PMID:
22527509
49.

Writing affects the brain network of reading in Chinese: a functional magnetic resonance imaging study.

Cao F, Vu M, Chan DH, Lawrence JM, Harris LN, Guan Q, Xu Y, Perfetti CA.

Hum Brain Mapp. 2013 Jul;34(7):1670-84. doi: 10.1002/hbm.22017. Epub 2012 Feb 29.

PMID:
22378588
50.

Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer.

Baquero MT, Hanna JA, Neumeister V, Cheng H, Molinaro AM, Harris LN, Rimm DL.

Cancer. 2012 Oct 1;118(19):4660-9. doi: 10.1002/cncr.27453. Epub 2012 Feb 22.

Supplemental Content

Loading ...
Support Center